Tags · Evidence
PIONEER programme
Oral semaglutide phase 3 programme.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · SUSTAIN programme · LEADER trial · randomised trial · meta-analysis · observational data
20 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small
Second pass at: Orforglipron as a non-peptide: what changes when the molecule is small Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021)…
|
2 | 17k | 6h | |
|
The SOUL trial and oral semaglutide cardiovascular outcomes
Posting this under the heading it deserves: The SOUL trial and oral semaglutide cardiovascular outcomes Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
|
2 | 7.1k | 9h | |
|
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please…
|
+25 | 29 | 22k | 1d |
|
About the Oral incretins category
Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 6.2k | 20d | |
|
Why fasting instructions for oral semaglutide are not optional advice
Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016)…
|
+70 | 74 | 1.1k | 23d |
|
Why oral semaglutide needs an absorption enhancer at all — one year on
Why oral semaglutide needs an absorption enhancer at all — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med , 2015) cited…
|
+11 | 15 | 17k | 24d |
|
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset
Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022)…
|
+27 | 31 | 17k | 25d |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on
Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…
|
+16 | 20 | 18k | 2mo |
|
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes
The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim I do not…
|
+100 | 104 | 4.2k | 5mo |
|
Dose numbers for oral formulations are not comparable to injectable ones
On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…
|
+19 | 23 | 39k | 6mo |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…
|
+130 | 135 | 11k | 7mo |
|
Oral versus injectable exposure: comparing apples to a different fruit
Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…
|
+19 | 23 | 332 | 8mo |
|
Why fasting instructions for oral semaglutide are not optional advice — does this still hold?
Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…
|
+98 | 106 | 3.1k | 10mo |
|
Food effects on oral incretin absorption: what is documented
On the subject in the title: Food effects on oral incretin absorption: what is documented Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
2 | 4.4k | 12mo | |
|
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…
|
+6 | 10 | 51k | 13mo |
|
Why oral semaglutide needs an absorption enhancer at all — what changed since
Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
2 | 61k | 14mo | |
|
SNAC and the mechanism of oral peptide absorption
On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…
|
+13 | 17 | 14k | 17mo |
|
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…
|
+48 | 52 | 59k | 18mo |
|
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
|
+141 | 154 | 47k | 19mo |
|
Orforglipron as a non-peptide: what changes when the molecule is small
On the subject in the title: Orforglipron as a non-peptide: what changes when the molecule is small Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURMOUNT-4 ( JAMA ,…
|
+26 | 30 | 26k | 23mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →